✦ LIBER ✦

Alternative drug delivery approaches for the therapy of inflammatory bowel disease

✍ Scribed by Yvette Meissner; Alf Lamprecht

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 457 KB
Volume: 97
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.21216

No coin nor oath required. For personal study only.

✦ Synopsis

This article shall give an overview on drug delivery systems for new therapeutic strategies in the treatment of inflammatory bowel disease. The various features of the different approaches allowing locally restricted drug delivery to the inflamed colon are discussed including the main physiological and pathophysiological limitations for the different systems. Conventional drug delivery systems are tightly adapted from developments for colonic delivery by oral administration triggered by release mechanisms owing to the physiological environment that these systems encounter in the colonic region. The newer developments in this context aim for an increased selectivity of drug delivery by targeting mechanisms which have a closer relation to pathophysiological particularities of the disease. Therefore, we were focused especially on new strategies for such treatment including liposomal formulations, cyclodextrins, micro-or nanoparticles, viral gene therapy approaches, and others. Effective and selective delivery even of an otherwise nonspecifically acting drug could provide new therapeutic pathways in the treatment of inflammatory bowel disease.

📜 SIMILAR VOLUMES

Therapeutic drug monitoring of biologics

Therapeutic drug monitoring of biologics for inflammatory bowel disease

✍ Jean-Frédéric Colombel; Brian G. Feagan; William J. Sandborn; Gert Van Assche; A 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

## Background: Although tumor necrosis factor (tnf) antagonists are effective for the treatment of crohn's disease and ulcerative colitis, lack and loss of clinical response is a clinical challenge. accordingly, the use of therapeutic drug monitoring has been proposed as a means to optimize treatme

Drug development in inflammatory bowel d

Drug development in inflammatory bowel disease: The role of the FDA

✍ Conor Lahiff; Sunanda Kane; Alan C. Moss 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 2 views

All medicinal compounds sold in the United States for inflammatory bowel disease (IBD) are regulated by the Food and Drug Administration (FDA) via a number of regulations dating back to 1906. The primary contemporary role of the FDA is in the assessment of safety and efficacy, and subsequent marketi

Biologic therapy in the management of ex

Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease

✍ Arthur Barrie; Miguel Regueiro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

The inflammatory bowel diseases (IBD), notably Crohn's disease (CD) and ulcerative colitis (UC), are systemic inflammatory diseases primarily involving the gastrointestinal tract. Twenty percent to 40% of patients with IBD develop extraintestinal inflammation and symptoms, known as extraintestinal m

Lost in translation: Helping patients un

Lost in translation: Helping patients understand the risks of inflammatory bowel disease therapy

✍ Corey A. Siegel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Patients with inflammatory bowel disease are commonly treated with immunomodulators and biologic therapy. These treatments can be very effective, but are associated with risks of adverse events that need to be discussed with patients. Effectively communicating risks of therapy can be challenging bas

Issues in the development of practice gu

Issues in the development of practice guidelines for inflammatory bowel disease

✍ Dr. William J. Tremaine 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB 👁 2 views

## A Practice guidelines for inflammatory bowel disease (IBD) should address the unique needs and challenges of the patients, to improve not only the quality of medical care but also the quality of life.

Guidelines for the management of growth

Guidelines for the management of growth failure in childhood inflammatory bowel disease

✍ Robert Heuschkel; Camilla Salvestrini; R. Mark Beattie; Hans Hildebrand; Thomas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

Around 1 in 4 patients with inflammatory bowel disease (IBD) present in childhood, the majority around the time of their pubertal growth spurt. This presents challenges over and above those of managing IBD in adults as this period is a time of dramatic psychological and physical transition for a chi